NASDAQ:ACER Acer Therapeutics - ACER Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acer Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $0.75 -0.01 (-1.32%) (As of 03/30/2023 12:00 AM ET) Add Compare Share Share Today's Range$0.73▼$0.7950-Day Range$0.67▼$2.4252-Week Range$0.65▼$4.56Volume321,439 shsAverage Volume452,537 shsMarket Capitalization$15.80 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Acer Therapeutics MarketRank™ ForecastAnalyst RatingN/AUpside/DownsideN/AShort InterestHealthy1.61% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.71Based on 9 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.23) to $0.71 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.51 out of 5 starsMedical Sector902nd out of 1,009 stocksPharmaceutical Preparations Industry439th out of 494 stocks N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Acer Therapeutics. Previous Next 3.0 Short Interest Percentage of Shares Shorted1.61% of the outstanding shares of Acer Therapeutics have been sold short.Short Interest Ratio / Days to CoverAcer Therapeutics has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Acer Therapeutics has recently increased by 14.41%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAcer Therapeutics does not currently pay a dividend.Dividend GrowthAcer Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ACER. Previous Next 3.2 News and Social Media Coverage News SentimentAcer Therapeutics has a news sentiment score of 0.71. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Acer Therapeutics this week, compared to 2 articles on an average week.Search Interest13 people have searched for ACER on MarketBeat in the last 30 days. This is an increase of 63% compared to the previous 30 days.MarketBeat Follows4 people have added Acer Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Acer Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders20.20% of the stock of Acer Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 27.96% of the stock of Acer Therapeutics is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Acer Therapeutics are expected to grow in the coming year, from ($0.23) to $0.71 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Acer Therapeutics is -0.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Acer Therapeutics is -0.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here About Acer Therapeutics (NASDAQ:ACER) StockAcer Therapeutics, Inc. is a pharmaceutical company. engages in acquisition, development and commercialization of therapies for medical needs. Its product pipeline includes ACER-001 Edsivo and ACER-2820. The Edsivo is a type of celiprolol for Vascular Ehlers-Danlos syndrome. The ACER-001 is for the treatment of urea cycle disorders and Maple Syrup Urine diseases. The company was founded on March 15, 1991 and is headquartered in Newton, MA.Read More Receive ACER Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Acer Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ACER Stock News HeadlinesMarch 30, 2023 | americanbankingnews.comEquities Analysts Set Expectations for Acer Therapeutics Inc.'s Q1 2023 Earnings (NASDAQ:ACER)March 29, 2023 | finanznachrichten.deAcer Therapeutics Inc.: Acer Therapeutics Reports Q4 and Full Year 2022 Financial Results and Provides Corporate UpdateMarch 30, 2023 | Behind the Markets (Ad)[BREAKING] New "Living Missile" to Replace Nuclear MissilesCBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!March 27, 2023 | finance.yahoo.comAcer Therapeutics Reports Q4 and Full Year 2022 Financial Results and Provides Corporate UpdateMarch 22, 2023 | finanznachrichten.deAcer Therapeutics Inc.: Acer Therapeutics Announces $2.675 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesMarch 22, 2023 | tmcnet.comAcer Therapeutics Announces Data Presented at Society for Inherited Metabolic Disorders Annual Meeting Identifying Preferred Urea Cycle DisorderMarch 22, 2023 | finance.yahoo.comAcer Therapeutics Announces $2.675 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesMarch 22, 2023 | finance.yahoo.comAcer Therapeutics Announces Data Presented at Society for Inherited Metabolic Disorders Annual Meeting Identifying Preferred Urea Cycle Disorder Treatment AttributesMarch 30, 2023 | Weiss Ratings (Ad)Bank Accounts: Frozen!In 1990, the Brazilian government froze the bank accounts of thousands of citizens. In 2013, the victims were the people of Cyprus. In 2022, it hit closer to home — in Canada. And now the Federal Reserve System Docket No. OP-1670 reveals the plan to give the Fed the power to track and potentially even control your checking account. Not just the money you have in your account … But also, every single check, withdrawal, deposit and transaction. Practically everything you do with your money!March 17, 2023 | reuters.comTwo new vaccines against bird flu effective in Dutch lab -govtMarch 17, 2023 | reuters.comUK healthcare workers to decide on new pay offer by end of April -unionsMarch 17, 2023 | finanznachrichten.deAcer Therapeutics Inc.: Acer Therapeutics Announces Topline Results from ACER-801 (Osanetant) Phase 2a TrialMarch 17, 2023 | seekingalpha.comAcer stock slumps ~45% as ACER-801 paused after hot flashes trial disappoints; cash woesMarch 17, 2023 | marketwatch.comAcer Therapeutics Shares Hit 52-Week Low After ACER-801 Trial Misses Topline ResultsMarch 17, 2023 | reuters.comAcer Therapeutics to pause trial of hot flashes drugMarch 17, 2023 | bizjournals.comNewton biotech's drug for hot flashes due to menopause fails trialMarch 17, 2023 | finance.yahoo.comAcer Therapeutics' Product Acquired From Sanofi Fails In Menopause StudyMarch 17, 2023 | finance.yahoo.comAcer Therapeutics Announces Topline Results from ACER-801 (Osanetant) Phase 2a TrialMarch 15, 2023 | finance.yahoo.comAcer Therapeutics Announces Presentation of HCP Urea Cycle Disorder Treatment Preference Data at the Society for Inherited Metabolic Disorders Annual Meeting and Provides OLPRUVA™ Program UpdateMarch 15, 2023 | uk.finance.yahoo.comRelief Therapeutics Provides Update From Collaboration Partner on OLPRUVA™March 15, 2023 | finance.yahoo.comRelief Therapeutics Provides Update From Collaboration Partner on OLPRUVAFebruary 18, 2023 | finance.yahoo.comACER Feb 2023 2.500 callFebruary 14, 2023 | finance.yahoo.comAcer Therapeutics Inc. (ACER) Interactive Stock Chart - Yahoo FinanceFebruary 13, 2023 | finance.yahoo.comAcer Therapeutics Announces Full Enrollment of Phase 2a Trial of ACER-801 (Osanetant) for Treatment of Moderate to Severe Vasomotor Symptoms Associated with MenopauseFebruary 10, 2023 | finance.yahoo.comAcer (ACER) to Report Q4 Earnings: What's in the Cards?January 27, 2023 | forbes.comAcer TherapeuticsJanuary 25, 2023 | finance.yahoo.comAcer Therapeutics Inc. (ACER) Gains As Market Dips: What You Should KnowSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive ACER Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Acer Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ACER Company Calendar Last Earnings11/19/2021Today3/30/2023Next Earnings (Estimated)5/15/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ACER CUSIPN/A CIK1069308 Webwww.acertx.com Phone(844) 902-6100Fax281-872-8585Employees35Year Founded2013Profitability EPS (Most Recent Fiscal Year)($1.66) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-15,370,000.00 Net MarginsN/A Pretax Margin-5,909.44% Return on EquityN/A Return on Assets-107.05% Debt Debt-to-Equity RatioN/A Current Ratio0.35 Quick Ratio0.35 Sales & Book Value Annual Sales$1.26 million Price / Sales12.54 Cash FlowN/A Price / Cash FlowN/A Book Value($0.12) per share Price / Book-6.25Miscellaneous Outstanding Shares21,070,000Free Float16,813,000Market Cap$15.80 million OptionableNot Optionable Beta0.65 Social Links Key ExecutivesChristopher SchellingPresident, Chief Executive Officer & DirectorTanya HaydenChief Operating OfficerHarry S. PalminChief Financial OfficerStacey BainVice President-Clinical OperationsAdrian QuartelChief Medical OfficerKey CompetitorsLexaria BioscienceNASDAQ:LEXXOnconova TherapeuticsNASDAQ:ONTXChembio DiagnosticsNASDAQ:CEMIBiofronteraNASDAQ:BFRIFrequency TherapeuticsNASDAQ:FREQView All CompetitorsInsiders & InstitutionsNantahala Capital Management LLCBought 529,653 shares on 2/15/2023Ownership: 7.693%Meridian Wealth Management LLCBought 71,750 shares on 2/15/2023Ownership: 0.450%Virtu Financial LLCSold 6,602 shares on 2/15/2023Ownership: 0.066%Geode Capital Management LLCBought 5,515 shares on 2/13/2023Ownership: 0.604%Renaissance Technologies LLCSold 9,100 shares on 2/13/2023Ownership: 0.367%View All Insider TransactionsView All Institutional Transactions ACER Stock - Frequently Asked Questions How have ACER shares performed in 2023? Acer Therapeutics' stock was trading at $2.51 at the beginning of 2023. Since then, ACER shares have decreased by 70.1% and is now trading at $0.75. View the best growth stocks for 2023 here. Are investors shorting Acer Therapeutics? Acer Therapeutics saw a increase in short interest in March. As of March 15th, there was short interest totaling 338,200 shares, an increase of 14.4% from the February 28th total of 295,600 shares. Based on an average daily volume of 556,500 shares, the days-to-cover ratio is currently 0.6 days. View Acer Therapeutics' Short Interest. When is Acer Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 15th 2023. View our ACER earnings forecast. How were Acer Therapeutics' earnings last quarter? Acer Therapeutics Inc. (NASDAQ:ACER) released its earnings results on Friday, November, 19th. The biopharmaceutical company reported ($0.23) earnings per share for the quarter, topping the consensus estimate of ($0.28) by $0.05. What is Jason Chen's approval rating as Acer Therapeutics' CEO? 64 employees have rated Acer Therapeutics Chief Executive Officer Jason Chen on Glassdoor.com. Jason Chen has an approval rating of 99% among the company's employees. This puts Jason Chen in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Acer Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Acer Therapeutics investors own include Novavax (NVAX), OPKO Health (OPK), Sorrento Therapeutics (SRNE), Sarepta Therapeutics (SRPT), Advanced Micro Devices (AMD), Amarin (AMRN), VBI Vaccines (VBIV), NVIDIA (NVDA), Idera Pharmaceuticals (IDRA) and Inovio Pharmaceuticals (INO). What is Acer Therapeutics' stock symbol? Acer Therapeutics trades on the NASDAQ under the ticker symbol "ACER." Who are Acer Therapeutics' major shareholders? Acer Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Nantahala Capital Management LLC (7.69%), Knott David M Jr (0.88%), Geode Capital Management LLC (0.60%), Meridian Wealth Management LLC (0.45%), Renaissance Technologies LLC (0.37%) and SVB Wealth LLC (0.07%). Insiders that own company stock include Chris Schelling, Donald Joseph and Steve Aselage. View institutional ownership trends. How do I buy shares of Acer Therapeutics? Shares of ACER stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Acer Therapeutics' stock price today? One share of ACER stock can currently be purchased for approximately $0.75. How much money does Acer Therapeutics make? Acer Therapeutics (NASDAQ:ACER) has a market capitalization of $15.80 million and generates $1.26 million in revenue each year. The biopharmaceutical company earns $-15,370,000.00 in net income (profit) each year or ($1.66) on an earnings per share basis. Does Acer Therapeutics have any subsidiaries? The following companies are subsidiares of Acer Therapeutics: Opexa Therapeutics Inc..Read More How can I contact Acer Therapeutics? Acer Therapeutics' mailing address is 300 WASHINGTON STREET SUITE 351, NEWTON MA, 02458. The official website for the company is www.acertx.com. The biopharmaceutical company can be reached via phone at (844) 902-6100, via email at hans@lifesciadvisors.com, or via fax at 281-872-8585. This page (NASDAQ:ACER) was last updated on 3/30/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.